摘要 A disease can be defined as an abnormal anatomy (pathology) and/or function (physiology) that may cause harm to the body. In clinical benign prostatic hyperplasis (BPH), the abnormal anatomy is prostate adenoma/adenomata, resulting in a varying degree of benign prostatic obstruction (BPO) that may cause harm to the bladder or kidneys. Thus clinical BPH can be defined as such and be differentiated from other less common causes of male lower urinary tract symptoms. Diagnosis of the prostate adenoma/adenomata (PA) can be made by measuring the intravesical prostatic protrusion (IPP) and prostate volume (PV) with non-invasive transabdominal ultrasound (TAUS) in the clinic. The PA can then be graded (phenotyped) according to IPP and PV. Multiple studies have shown a good correlation between IPP/PV and BPO, and therefore progression of the disease. The severity of the disease clinical BPH can be classified into stages from stage I to IV for further management. The classification is based on the effect of BPO on bladder functions, namely that of emptying, normal if postvoid residual urine (PVRU) < 100 mL; and bladder storage, normal if maximum voided volume (MVV) > 100 mL. The effect of BPO on quality of life (QoL) can be assessed by the QoL index, with a score ≥ 3 considered bothersome. Patients with no significant obstruction and no bothersome symptoms would be stage I; those with no significant obstruction but has bothersome symptoms (QoL ≥ 3) would be stage Ⅱ; those with significant obstruction (PVRU > 100 mL; or MVV < 100 mL), irrespective of symptoms would be stage Ⅲ; those with complications of the disease clinical BPH such as retention of urine, bladder stones, recurrent bleeding or infections would be stage IV. After assessment, further management can then be individualised. A low grade and stage disease can generally be watched (active surveillance) while a high grade and stage disease would need more invasive management with an option for surgery. The final decision making would take into account the patient's age, co-morbidity, social economic background and his preferences/values. Proper understanding of pathophysiology of clinical BPH would lead to better selection of patients for individualised and personalised care and more cost effective management.
Abstract: A disease can be defined as an abnormal anatomy (pathology) and/or function (physiology) that may cause harm to the body. In clinical benign prostatic hyperplasis (BPH), the abnormal anatomy is prostate adenoma/adenomata, resulting in a varying degree of benign prostatic obstruction (BPO) that may cause harm to the bladder or kidneys. Thus clinical BPH can be defined as such and be differentiated from other less common causes of male lower urinary tract symptoms. Diagnosis of the prostate adenoma/adenomata (PA) can be made by measuring the intravesical prostatic protrusion (IPP) and prostate volume (PV) with non-invasive transabdominal ultrasound (TAUS) in the clinic. The PA can then be graded (phenotyped) according to IPP and PV. Multiple studies have shown a good correlation between IPP/PV and BPO, and therefore progression of the disease. The severity of the disease clinical BPH can be classified into stages from stage I to IV for further management. The classification is based on the effect of BPO on bladder functions, namely that of emptying, normal if postvoid residual urine (PVRU) < 100 mL; and bladder storage, normal if maximum voided volume (MVV) > 100 mL. The effect of BPO on quality of life (QoL) can be assessed by the QoL index, with a score ≥ 3 considered bothersome. Patients with no significant obstruction and no bothersome symptoms would be stage I; those with no significant obstruction but has bothersome symptoms (QoL ≥ 3) would be stage Ⅱ; those with significant obstruction (PVRU > 100 mL; or MVV < 100 mL), irrespective of symptoms would be stage Ⅲ; those with complications of the disease clinical BPH such as retention of urine, bladder stones, recurrent bleeding or infections would be stage IV. After assessment, further management can then be individualised. A low grade and stage disease can generally be watched (active surveillance) while a high grade and stage disease would need more invasive management with an option for surgery. The final decision making would take into account the patient's age, co-morbidity, social economic background and his preferences/values. Proper understanding of pathophysiology of clinical BPH would lead to better selection of patients for individualised and personalised care and more cost effective management.
作者简介: Keong Tatt Foo,E-mail address:foo.keong.tatt@singhealth.com.sg.
引用本文:
Keong Tatt Foo. Pathophysiology of clinical benign prostatic hyperplasia[J]. Asian Journal of Urology, 2017, 4(3): 152-157.
Keong Tatt Foo. Pathophysiology of clinical benign prostatic hyperplasia. Asian Journal of Urology, 2017, 4(3): 152-157.
[1] Gratzke C, Bachmann A, Descazeaud A, Drake MJ, Madersbacher S, Mamoulakis C, et al. EAU guidelines on the assessment of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. Eur Urol 2015;67:1099-109. [2] Luo GC, Foo KT, Kuo T, Tan G. Diagnosis of prostate adenoma and the relationship of its site to bladder outlet obstruction. Singapore Med J 2013;54:482-6. [3] Foo KT. From evidence-based medicine to evidence-balanced medicine for individualized and personalized care:as applied to benign prostatic hyperplasia/male lower urinary tract symptoms. Int J Urol 2017;24:94-5. [4] McNeal JE. Normal histology of the prostate. Am J Surg Pathol 1988;12:619-33. [5] Randall A. Surgical pathology of prostatic obstruction. Baltimore:Williams & Wilkins; 1931. [6] Babinski MA, Manaia JH, Cardoso GP, Costa WS, Sampaio FJ. Significant decrease of extracellular matrix in prostatic urethra of patients with benign prostatic hyperplasia. Histol Histopathol 2014;29:57-63. [7] Cardoso LE, Falcao PG, Sampaio FJ. Increased and localized accumulation of chondroitin sulphate proteoglycans in the hyperplastic human prostate. BJU Int 2004;93:532-8. [8] Yuen JS, Ngiap JT, Cheng CW, Foo KT. Effects of bladder volume on transabdominal ultrasound measurements of intravesical prostatic protrusion and volume. Int J Urol 2002;9:225-9. [9] Tan YH, Foo KT. Intravesical prostatic protrusion predicts the outcome of a trial without catheter following acute urine retention. J Urol 2003;170:2339-41. [10] Foo KT, Lee LS. Re:intravesical prostatic protrusion (IPP) and uroflowmetry in the management of benign prostatic enlargement (BPE). Int J Urol 2010;17:589. [11] Winters JC, Dmochowski RR, Goldman HB, Herndon CD, Kobashi KC, Kraus SR, et al. Urodynamic studies in adults:AUA/SUFU guideline. J Urol 2012;188:2464-72. [12] Chia SJ, Heng CT, Chan SP, Foo KT. Correlation of intravesical prostatic protrusion with bladder outlet obstruction. BJU Int 2003;91:371-4. [13] Lee LS, Sim HG, Lim KB, Wang D, Foo KT. Intravesical prostatic protrusion predicts clinical progression of benign prostatic enlargement in patients receiving medical treatment. Int J Urol 2010;17:69-74. [14] Tiong HY, Tibung MJ, Macalalag M, Li MK, Consigliere D. Alfuzosin 10 mg once daily increases the chances of successful trial without catheter after acute urinary retention secondary to benign prostate hyperplasis. Urol Int 2009;83:44-8. [15] Mariappan P, Brown DJ, McNeill AS. Intravesical prostatic protrusion is better than prostate volume in predicting the outcome of trial without catheter in white men presenting with acute urinary retention:a prospective clinical study. J Urol 2007;178:573-7. [16] Wang D, Huang H, Law YM, Foo KT. Relationships between prostatic volume and intravesical prostatic protrusion on transabdominal ultrasound and benign prostatic obstruction in patients with lower urinary tract symptoms. Ann Acad Med Singapore 2015;44:60-5. [17] Cumpanas AA, Botoca M, Minciu R, Bucuras V. Intravesical prostatic protrusion can be a predicting factor for the treatment outcome in patients with lower urinary tract symptoms due to benign prostatic obstruction treated with tamsulosin. Urology 2013;81:859-63. [18] McNeill SA, Hargreave TB, Geffriaud-Ricouard C, Santoni JP, Roehrborn CG. Postvoid residual urine in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia:pooled analysis of eleven controlled studies with alfuzosin. Urology 2001;57:459-65. [19] Rosier PF, de Wildt MJ, Wijkstra H, Debruyne FF, de la Rosette JJ. Clinical diagnosis of bladder outlet obstruction in patients with benign prostatic enlargement and lower urinary symptoms:development and urodynamic validation of a clinical prostate score for the objective diagnosis of bladder outlet obstruction. J Urol 1996;155:1649-54. [20] Sirls LT, Kirkemo AK, Jay J. Lack of correlation of the American urological association symptom 7 index with urodynamic bladder outlet obstruction. Neurourol Urodyn 1996;15:447-56. [21] Bosch JL, Hop WC, Kirkels WJ, Schröder FH. The International Prostate Symptom Score in a community-based sample of men between 55 and 74 years of age:prevalence and correlation of symptoms with age, prostate volume, flow rate and residual urine volume. Br J Urol 1995;75:622-30. [22] Wadie BS, Ibrahim EH, de la Rosette JJ, Gomha MA, Ghoneim MA. The relationship of the International Prostate Symptom Score and objective parameters for diagnosing bladder outlet obstruction. Part 1:when statistics fail. J Urol 2001;165:32-4. [23] Foo KT. Current assessment and proposed staging of patients with benign prostatic hyperplasia. Ann Acad Med Singapore 1995;24:648-51. [24] Wang D, Foo KT. Staging of benign prostate hyperplasia is helpful in patients with lower urinary tract symptoms suggestive of benign prostate hyperplasia. Ann Acad Med Singapore 2010;39:798-802. [25] Ball AJ, Feneley RC, Abrams PH. The natural history of untreated "prostatism". Br J Urol 1981;53:613-6. [26] McVary KT, Roehrborn CG, Avins AL, Barry MJ, Bruskewitz RC, Donnell RF, et al. Update on AUA guideline on the management of benign prostatic hyperplasia. J Urol 2011;185:1793-803.
Christopher Hartman, Nikhil Gupta, David Leavitt, David Hoenig, Zeph Okeke, Arthur Smith. Advances in percutaneous stone surgery[J]. Asian Journal of Urology, 2015, 2(1): 26
-32
.
